Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

156.40B

Market cap156.40B

Price-Earnings ratio

17.19

Price-Earnings ratio17.19

Dividend yield

2.55%

Dividend yield2.55%

Average volume

9.69M

Average volume9.69M

High today

$127.62

High today$127.62

Low today

$125.13

Low today$125.13

Open price

$127.36

Open price$127.36

Volume

6.19M

Volume6.19M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$107.75

52 Week low$107.75

Stock Snapshot

The current Gilead Sciences(GILD) stock price is $125.97, with a market capitalization of 156.4B. The stock trades at a price-to-earnings (P/E) ratio of 17.19 and offers a dividend yield of 2.55%.

On 2026-07-01, Gilead Sciences(GILD) stock moved within a range of $125.13 to $127.62. With shares now at $125.97, the stock is trading +0.7% above its intraday low and -1.3% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 6.19M, versus its average volume of 9.69M.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $107.75.

GILD News

The Wall Street Journal 1d

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ

...

Nasdaq 2d

Gilead Moves 3.3% Higher: Will This Strength Last?

Gilead Sciences (GILD) shares rallied 3.3% in the last trading session to close at $127.88. This move can be attributable to notable volume with a higher number...

Simply Wall St 2d

Gilead Sciences Trodelvy Approval Puts Its Valuation Story Back In Focus

Gilead Sciences (GILD) is back in focus after Trodelvy secured U.S. FDA approval and European marketing authorization as a first-line treatment for unresectable...

Analyst ratings

79%

of 29 ratings

Buy

79.3%

Hold

20.7%

Sell

More GILD News

Simply Wall St 4d

How Trodelvy’s New First-Line Breast Cancer Role Could Reframe Gilead Sciences’ Investment Narrative

Earlier this week, Gilead Sciences reported that regulators in the US and Europe approved expanded first-line use of Trodelvy for unresectable locally advanced...

Simply Wall St 5d

Gilead Wins FDA Approval For Trodelvy In First Line Triple Negative Breast Cancer

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy as a first-line treatment for adult patients with advanced or metastatic triple-negative brea...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.